Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
about
Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisClinical correlates of common corneal neovascular diseases: a literature reviewAsian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy.Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses.Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivoHypothesis: thalidomide embryopathy-proposed mechanism of action.Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases.Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.Effect of thalidomide on the expression of vascular endothelial growth factor in a rat model of liver regeneration.Thalidomide: an old drug with new clinical applications.Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization.Thalidomide and its derivatives: emerging from the wilderness.Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysisHepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review.A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinomaInhibitory effects of (90)Sr/(90)Y β-irradiation on alkali burn-induced corneal neovascularization in ratsAntiangiogenic therapy in brain tumors.Novel aspects of corneal angiogenic and lymphangiogenic privilege.Angiogenesis in head and neck cancer: a review of the literature.Thalidomide: features and potential significance in oral precancerous conditions and oral cancer.Current and Upcoming Therapies for Ocular Surface Chemical Injuries.Arsenic trioxide enhances the cytotoxic effect of thalidomide in a KG-1a human acute mylogenous leukemia cell lineEffect of thalidomide and arsenic trioxide on the release of tumor necrosis factor-α and vascular endothelial growth factor from the KG-1a human acute myelogenous leukemia cell line.Concise asymmetric synthesis of configurationally stable 4-trifluoromethyl thalidomide.DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture.Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease.Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma.Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion.Differential effects of antiangiogenic compounds in neovascularization, leukocyte recruitment, VEGF production, and tumor growth in mice.Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in vivo rabbit model.Effect of thalidomide on the healing of colonic anastomosis, in rats.alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma.Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.Testing the angiogenic potential of cerebrovascular malformations by use of a rat cornea model: usefulness and novel assessment of changes over time.
P2860
Q27026453-835B4D68-D675-43AF-BAB4-DB65857FE6D1Q28257676-6669A7BC-5889-4C2D-B6C8-59DC3930176FQ30479629-5FFBCA22-E1E0-4D0F-A00D-B1E71447368EQ30642886-74B9DCC3-E8C7-4E37-A557-CAB4946AE32AQ33753486-8B2664FA-D88C-4C44-B9AC-472891D402F8Q33816513-3CE40243-84CB-40F0-A7CE-9849E6793C3AQ33831075-F692EB64-E4A1-42EA-B70A-FFE6F424AEF9Q33932989-0AD1654F-6506-4ED7-8A06-B9355801DD17Q34382640-991968AB-2BE8-4ACC-A592-7D9E2C0AE324Q34453644-EFFA96BB-7648-4EBD-82F2-E1D28D14C19AQ34454532-4795DCF7-8F1D-4A45-BED5-EC8CC2FF71DFQ34593576-B9DFC045-C724-45A7-90DA-BDB223E1EFACQ34798767-21CC23B7-CBD2-47C4-B3ED-C3D890CBD44AQ35103846-423050A7-0F46-492F-9D11-1051EB407C55Q35107977-CB38C220-8D61-43E3-A412-F373A1730481Q35175287-145B3A4F-34E5-4805-8A89-B1A407821578Q35725800-F03AEB89-BE25-4892-B9BE-F58C2F4334F0Q35959347-24395D79-4FA7-4091-991E-6C8E58A754F3Q36509683-074405D7-FE00-4228-BDBA-A10C794C00F6Q36524407-87704A30-ACAD-4E0F-A633-5B139DD0E325Q37129915-CB407C64-623F-4D2D-A219-A2871E184DEAQ37681157-3B3AAA3F-5533-419F-AEF9-9AE60FE8F8D5Q37963379-A448C656-8677-4519-86DA-B602030A7CA3Q38043509-AEFDA0FA-BCD6-4DB8-9AA8-B51971EABE48Q38819339-59EB2242-B876-4AD4-943D-7B1215DDC997Q39569681-77845445-7EC3-4690-AC8B-6896B428F4C7Q39687272-E4E1C6E4-C10C-489F-970D-020FA3E987E4Q39959248-7D84C560-E838-4513-A1B9-5BDC8E4AD358Q42064067-FEC86C71-E86C-40AE-9B27-E37CD5F5CD34Q42674768-7A78A52B-110C-48AE-B73E-7D5F4E8ADD64Q44041377-C5A57CFC-3BC9-4532-B4E8-A65808563018Q44412205-557164A2-7F2E-4405-8259-B0F93A0284DDQ45174628-E0282F57-5192-4CA0-83D4-1B7A4158D5A7Q45259635-E1586006-53E4-4A5D-B737-913008122B64Q46564328-203422E7-7827-45FA-AF0A-F8D0E6004CC5Q46642643-C2F04226-556A-4A7A-8A2E-0B273862E99FQ47096268-6E2609D3-67B3-401A-94D0-07675DDBEA4AQ47692343-563684D2-EF62-4E51-91BF-DB208A23C68BQ48226736-E56B1655-51BC-48BA-BCF2-D4151C1B2A4AQ48883513-169ACEB2-C3A9-4971-BEC7-5BFCB0121BAB
P2860
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
@en
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
@nl
type
label
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
@en
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
@nl
prefLabel
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
@en
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
@nl
P2093
P356
P1476
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
@en
P2093
Joussen AM
Rohrschneider K
Völcker HE
P2888
P304
P356
10.1007/S004170050106
P577
1998-06-01T00:00:00Z